Rystiggo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of autoimmune disease mechanisms, increasing diagnosis rates of gMG, advancements in monoclonal antibody engineering, availability of specialty infusion therapies, expansion of neurology specialty care.

The growth in the forecast period can be attributed to increasing investments in autoimmune biologics, rising demand for disease-modifying therapies, expansion of precision immunology research, growing adoption of home-based infusion models, advancement of next-generation antibody platforms. Major trends in the forecast period include increasing adoption of fcrn inhibitor therapies, rising demand for targeted autoimmune treatments, growing preference for subcutaneous biologic delivery, expansion of precision neurology therapeutics, enhanced focus on patient-centric treatment regimens.

The increasing prevalence of myasthenia gravis is expected to drive the growth of the rystiggo market going forward. Myasthenia gravis (MG) is a chronic autoimmune condition that affects the neuromuscular junction, leading to weakness in voluntary skeletal muscles. The growing prevalence of myasthenia gravis is attributed to improved diagnostic capabilities, an aging population, heightened disease awareness, enhanced reporting systems, and longer life expectancy among affected individuals. Rystiggo (rozanolixizumab) is a monoclonal antibody therapy used to treat myasthenia gravis by targeting and inhibiting the neonatal Fc receptor (FcRn). For instance, in February 2024, according to the National Institutes of Health, a U.S.-based government agency, approximately 82,715 adults in the United States were living with myasthenia gravis in 2021, corresponding to an estimated prevalence of 320.2 cases per million people. Therefore, the rising prevalence of myasthenia gravis is driving the growth of the rystiggo market.

The rise in healthcare expenditure is expected to support the growth of the rystiggo market in the coming years. Healthcare expenditure encompasses total spending on medical services, healthcare products, and public health initiatives aimed at maintaining and improving health. The increase in healthcare spending is driven by an aging population requiring more medical care, along with the growing incidence of chronic conditions such as diabetes and cardiovascular diseases. Healthcare expenditure related to rystiggo includes medication costs, infusion services, patient monitoring, specialty pharmacy services, and support programs for the management of generalized myasthenia gravis. For instance, in November 2024, according to the Health Foundation, a UK-based independent charity, the Department of Health and Social Care’s planned daily spending is projected to rise from approximately $219.5 billion (£177.9 billion) to $239.3 billion (£190.1 billion) in 2024/25, and further to $254.5 billion (£200.5 billion) in 2025/26. Therefore, the increasing healthcare expenditure is driving the expansion of the rystiggo market.

The rystiggo market is witnessing a key trend focused on the development of innovative therapies, including new treatments for generalized myasthenia gravis, to address unmet medical needs, enhance patient outcomes, and strengthen competitive positioning. Treatment for generalized myasthenia gravis typically involves symptom control through acetylcholinesterase inhibitors, immunosuppressive agents, targeted biologic therapies, and interventions such as plasma exchange or thymectomy to reduce autoantibody activity and improve muscle strength. For instance, in June 2023, UCB Inc., a Belgium-based pharmaceutical company, received FDA approval for RYSTIGGO (rozanolixizumab-noli), making it the first therapy specifically approved for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. The approval was supported by positive results from the Phase 3 MycarinG study, which demonstrated significant improvements in patients’ daily functioning. RYSTIGGO is administered as a once-weekly subcutaneous infusion over six weeks, and its approval has been well received by patient advocacy groups for its potential to address unmet needs within the generalized myasthenia gravis community.

Major companies operating in the rystiggo market are UCB Inc.

North America was the largest region in the rystiggo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rystiggo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rystiggo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the rystiggo market by increasing costs of imported biologic manufacturing equipment, antibody production materials, sterile injection components, and cold-chain distribution systems. North America and Europe are most impacted due to dependence on globally sourced monoclonal antibody inputs, while Asia-Pacific faces cost pressure in export-oriented biologics manufacturing. These tariffs are raising overall treatment costs and affecting reimbursement dynamics. At the same time, they are encouraging domestic biologics production, regional fill-finish expansion, and strategic investments in localized antibody manufacturing capabilities.

The rystiggo market research report is one of a series of new reports that provides rystiggo market statistics, including rystiggo industry global market size, regional shares, competitors with a rystiggo market share, detailed rystiggo market segments, market trends and opportunities, and any further data you may need to thrive in the rystiggo industry. This rystiggo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rystiggo is the brand name for rozanolixizumab-noli, a medication used to treat generalized myasthenia gravis (gMG) in adults. It is administered as a subcutaneous infusion and works by targeting the neonatal Fc receptor (FcRn), thereby reducing pathogenic IgG autoantibodies that contribute to the disease.

The main treatment approaches for Rystiggo include monotherapy and combination therapy. Monotherapy involves managing a disease or condition with a single drug or therapeutic agent rather than using multiple medications together. The primary clinical indications include generalized myasthenia gravis (gMG) and, off-label, certain autoimmune neurological disorders. The medication is distributed through various channels such as hospitals, clinics, and diagnostic centers.

The rystiggo market consists of sales of products including efgartigimod alfa-fcab (Vyvgart), zilucoplan (Zilbrysq), and eculizumab (Soliris). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.